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A B S T R A C T
Dopamine (DA) transmission is governed by processes that regulate release from axonal boutons in the
forebrain and the somatodendritic compartment in midbrain, and by clearance by the DA transporter,
diffusion, and extracellular metabolism. We review how axonal DA release is regulated by neuronal
activity and by autoreceptors and heteroreceptors, and address how quantal release events are regulated
in size and frequency. In brain regions densely innervated by DA axons, DA clearance is due
predominantly to uptake by the DA transporter, whereas in cortex, midbrain, and other regions with
relatively sparse DA inputs, the norepinephrine transporter and diffusion are involved. We discuss the
role of DA uptake in restricting the sphere of inﬂuence of DA and in temporal accumulation of
extracellular DA levels upon successive action potentials. The tonic discharge activity of DA neurons may
be translated into a tonic extracellular DA level, whereas their bursting activity can generate discrete
extracellular DA transients.
ã 2016 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Contents
1. Regulation of dopamine release . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 124
1.1. Dopamine release by synaptic vesicle fusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 124
1.1.1. Quantal release and detection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 124
1.1.2. The synaptic vesicle cycle . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 125
1.1.3. DA synaptic vesicle fusion structure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 126
1.2. How much DA is in a synaptic vesicle? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 126
1.2.1. Altered free energy for vesicular DA sequestration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127
1.2.2. Roles of pH, electrical gradients, and amphetamines on vesicular dopamine uptake . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127
1.2.3. Roles of Cl, glutamate, and GABA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 128
1.2.4. Intravesicular storage capacity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 128
1.2.5. L-DOPA and dopamine synthesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 129
1.2.6. VMAT2 activity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 129
1.3. Regulation of the number of synaptic vesicles that fuse . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 130
1.3.1. Ca2+ dependence of dopamine release . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 130
Contents lists available at ScienceDirect
Basal Ganglia
journa l home page : www.e l sev ier .com/ loca te /baga* Corresponding authors.
E-mail addresses: ds43@cumc.columbia.edu (D. Sulzer),
stephanie.cragg@dpag.ox.ac.uk (S.J. Cragg), margaret.rice@nyu.edu (M.E. Rice).
http://dx.doi.org/10.1016/j.baga.2016.02.001
2210-5336/ã 2016 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
124 D. Sulzer et al. / Basal Ganglia 6 (2016) 123–1481.3.2. Regulation of fusion modes by synaptic proteins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 130
1.4. Regulation of axonal dopamine release by autoreceptors and heteroreceptors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 130
1.4.1. Dopamine autoreceptors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 130
1.4.2. Glutamate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 132
1.4.3. GABA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 133
1.4.4. Acetylcholine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 133
1.4.5. Opioids . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 135
1.4.6. Neuropeptides: Substance P, insulin, growth factors, and CRF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 135
1.4.7. Adenosine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 136
1.4.8. Cannabinoids and others modulators . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 136
1.5. Relationship between ﬁring and vesicular release . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 136
1.5.1. Frequency dependent modulation of dopamine release . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 136
1.5.2. Silent dopamine release sites? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 136
2. Dopamine uptake . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 136
2.1. Kinetics of dopamine uptake . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 137
2.2. DAT regulation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 137
2.2.1. DAT regulation by psychostimulants . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 137
2.2.2. DAT regulation by D2 receptors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 137
2.3. Uptake limits the radius of DA diffusion in the extracellular space . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 138
3. Relationship between DA neuron ﬁring and extracellular DA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 138
3.1. Tonic [DA]o . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 138
3.2. Phasic changes in [DA]o . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 139
4. Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 139
Disclosure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 139
Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 139
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1391. Regulation of dopamine release
Dopamine (DA) neurotransmission is generally initiated by the
fusion of synaptic vesicles in axonal boutons, with the exceptions
of release by amphetamine-like drugs that can release DA via
reverse transport through the DA uptake transporter (DAT) [1,2],
and DA release from dendrites, which is widely suspected to occur
via fusion of specialized secretory organelles [3]. This process is
regulated at many levels, including DA synthesis, uptake and
vesicular transport, as well as by Ca2+ homeostasis and regulatory
exocytotic proteins. In addition, neurotransmitter receptors on DA
neurons, axons, and dendrites provide feedback, regulate DA
release, and in some conditions locally drive DA release.
1.1. Dopamine release by synaptic vesicle fusion
1.1.1. Quantal release and detection
In 1950, Bernard Katz and Paul Fatt published recordings of
random electrical “noise” consisting of spontaneous small
“action potentials” (a term now used quite differently) at frog
neuromuscular junction they compared to “ﬂuctuations in the
number of light quanta which strike the [photo]receptor cells”
[4]. These “miniature end plate potentials” required extracellular
Ca2+ and were exacerbated by high osmolarity [5]. The events ﬁt
a Poisson distribution, which simulates the probability of
random occurrences of multiple basic events [6], indicating
that neurotransmission occurs in multiples of a “quantal” unit.
They conjectured that “the apparatus for the release of
acetylcholine (ACh) at a junction is subdivided into a large
number of units (at least 100), each of which is able to operate
independently of the rest” [7].
In contrast to ionotropic ACh receptors, DA primarily activates G
protein-coupled receptors that do not produce small rapid
currents, and so a means to detect quantal DA release was elusive.
An effective approach was provided by electrochemical catechol-
amine detection, introduced by Ralph Adams and colleagues [8–
10]. These methods were improved by the introduction of carbon-
ﬁber microelectrodes for detection of catecholamines by Francois
Gonon [11] and Michael Armstrong-James and Julian Millar [12,13].Armstrong-James and Millar [14] also developed the method of
fast-scan cyclic voltammetry (FCV) with carbon-ﬁber electrodes,
which is widely used for monitoring DA release and uptake in vivo
and in ex vivo brain slices.
The ﬁrst analysis of quantal release of catecholamines used
large secretory vesicles from the adrenal gland. Extracts from
adrenal cells provided the original evidence for secretory
transmission [15]. In 1990, Mark Wightman and colleagues [16]
used amperometry to detect quantal catecholamine release from
adrenal cells. In contrast to postsynaptic recording, amperometric
recording indicates directly the number of molecules released and
the duration of a quantal release event, which in adrenal
chromafﬁn cells is about 106 molecules over the course of
101 s.
Amperometric recording was then adapted to record from
axonal terminals of cultured midbrain DA neurons. Synaptic
vesicles in these axons are 40 nm in diameter, with a volume that
is 1000-fold smaller than that of adrenal chromafﬁn granules,
with proportionally smaller quantal events that are of shorter
duration than those from adrenal cells [17,18]. The released
catecholamine was identiﬁed as DA based on: (1) blockade by
reserpine, a vesicular monoamine transporter type 2 (VMAT2)
inhibitor; (2) colocalization with tyrosine hydroxylase (TH); (3) the
potential required for DA oxidation; (4) absence of detection from
neurons that lack DA; and (5) elevation of quantal size following
exposure to L-DOPA, a DA precursor, or increased
VMAT2 expression. The shape of the majority of quantal DA
events in neurons closely ﬁt a simulation of transmitter diffusion
through a pore [19], but some release events that deviate from such
simple shapes (see Section 1.1.3).
In cultured DA neurons, quantal events have been recorded
from boutons in axons, and from acutely dissociated DA somata
[20], which may represent quantal somatodendritic release events
or release of synaptic vesicle precursors that would have been
trafﬁcked to axons. Release events have also been found in acute
midbrain slices, although it is difﬁcult to exclude release from
nearby DA or serotonin terminals [21]. It seems likely that
occasional DA secretion occurs at cell bodies, as
VMAT2 transfection of hippocampal neurons can produce quantal
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Electron microscope (EM) studies show few obvious synaptic
vesicle-like organelles in DA dendrites, but rather that VMAT2 is
found primarily in tubular structures [3]. Quantal DA release from
synaptic vesicles has also been recorded by amperometry from
retinal bipolar cells [23] and invertebrate neuronal cell bodies
[24,25].
Spontaneous DA release events, some of which may represent
individual quanta, have been recorded postsynaptically after
lentiviral-mediated expression of an anion channel, LGC-53, from
C. elegans in striatal medium spiny neurons [26]. Another new
technique for DA detection is the use of cell-based neurotransmit-
ter ﬂuorescent engineered reporters or “CNiFERs” which after
transfection can produce ﬂuorescent responses to a variety of
transmitters that activate G-protein coupled receptors, including
DA [27]. Another recent optical technique is provided by
ﬂuorescent false neurotransmitters that are substrates for
VMAT2 and in some cases DAT, and which can be accumulated
and released from DA synaptic vesicles [28,29]. Recent evidence
suggests that the majority of sites with many synaptic vesicles in
striatal DA axons may not exhibit fusion, even when accompaniedFig. 1. Features of synaptic vesicle activity in dopamine axons.
(A) Fates of synaptic vesicle membrane. Striatal dopamine (DA) release sites are en passan
both axons and boutons and a smaller number of dense core vesicles (DCV) that are t
components following membrane recycling from endosomes. The source of vesicular DA c
of extracellular DA by the DA transporter (DAT), with subsequent accumulation in vesicle
fusion in a ﬂickering mode (“complex event”) that involves transient and reversible ex
membrane is recycled via an endosomal intermediate, via either “bulk endocytosis” or 
retrograde transport and lysosomal degradation [69]. Recent evidence suggests that th
(B) A vastly simpliﬁed DA synaptic vesicle showing some features discussed in this article.
two protons for each DA molecule, the vacuolar vesicular ATPase (vATPase) that pumps pr
synaptic vesicles is likely ClC-3) that provides net counterions (probably with proton efﬂu
SNARE protein, VAMP, a.k.a. synaptobrevin, involved in synaptic vesicle fusion via formati
might also possess the glutamate vesicular transporter, VGLUT2.by depolarization-induced increase in intracellular Ca2+ concen-
tration (Pereiera et al. [30]).
1.1.2. The synaptic vesicle cycle
The fundamental difference between quantal release of
catecholamines from secretory glands and central DA neurons is
the secretory vesicles involved. In adrenal medullary cells, the
large (150–300 nm diameter) “chromafﬁn granules” [31] that
accumulate catecholamines [32,33] fuse with the plasma mem-
brane to exocytose transmitter, but do not recycle locally to
produce new storage vesicles.
In contrast, the synaptic vesicle “cycle” leads to a range of
means to regulate synaptic transmission. Soon after early EM
images of synapses revealed small (40–50 nm diameter) “synap-
tic vesicles” in axon terminals [34,35], Sanford Palay made a link to
Fatt’s conjecture from quantal recording, writing “The heretofore
unrecognized structure demanded by these physiological data may
be the small vesicles which crowd the axon terminals, cluster at the
junctional surface, and open onto the intrasynaptic space” [36].
Indeed, catecholamine synaptic vesicles played an important role
in conﬁrming the synaptic vesicle hypothesis, as they accumulatet structures on long and highly branched axons, with many small synaptic vesicles in
hought to both undergo exocytosis and deliver small synaptic vesicle membrane
an be from synthesis via tyrosine hydroxylase (TH) action on L-DOPA or from uptake
 by the vesicular monoamine transporter, VMAT2. Synaptic DA vesicles can undergo
ocytosis [17] or can undergo full fusion (“simple event”). After full fusion, vesicle
clathrin-coated intermediates. The endosomes may fuse with autophagosomes for
e majority of sites with many synaptic vesicles may not exhibit fusion [30].
 These include the DA transporter VMAT2 which is thought to provide net antiport of
otons to the vesicle interior, an anion channel (the predominant chloride channel in
x) to decreases the free energy required for the proton gradient DA uptake, and a v-
on of a SNARE complex with plasma membrane t-SNARES. Some DA synaptic vesicles
126 D. Sulzer et al. / Basal Ganglia 6 (2016) 123–148osmophilic catecholamine reaction products [37] and the osmo-
philic false transmitter 5-hydroxy-DA [38].
Eric Holtzman [39] and subsequently Bruno Ceccarelli [40]
showed that ﬂuid phase endocytic tracers such as horseradish
peroxidase are accumulated by synaptic vesicles during stimula-
tion, and that after the tracer is removed, further stimulation
eliminates the label. Thus, synaptic vesicle membrane is endocy-
tosed from the plasma membrane following full fusion and
synaptic vesicles are re-formed (i.e., recycled) and then undergo
further bouts of fusion to release the tracer (Fig. 1A). Early studies
indicated that some vesicles may fuse transiently via a fusion pore
without full fusion [41–43], a process typically known as “kiss-
and-run” fusion, and although established for large dense core
vesicles [44], this phenomenon has long remained controversial
for small synaptic vesicles. In the case of DA axons, amperometric
recordings of quantal release are consistent with “ﬂickering”
transient fusion pore formation. The recycling of synaptic vesicles
can be modeled as a series of kinetic steps, each of which can be
regulated to alter neurotransmitter release (Fig. 1B). These include
uptake of neurotransmitter by speciﬁc transporters that utilize an
energy gradient formed by an ATP-driven proton pump, trafﬁcking
of vesicles to a presynaptic release site, a “docking” step that
tethers the vesicle to its eventual site of fusion with the plasma
membrane, a “priming” step during which the docked vesicle is
placed in a fusion-ready state, a fusion step which may proceed via
full fusion with the membrane or transient fusion [17], and a series
of recycling steps leading to vesicle reformation.
1.1.3. DA synaptic vesicle fusion structure
Amperometric recordings from chromafﬁn and mast cells
suggest that the fusion pore during large dense-core vesicle fusion
can exist in at least two states, a “foot” that represents a small
(3 nm diameter) reversible fusion pore, and a full event that is
often interpreted to indicate full fusion [45–48]. Such ﬁndings
suggest that fusion pore modulation is capable of affecting the
amount and kinetics of transmitter release.
The study of vesicle fusion modes in axons of DA neurons has
been hampered by their small size. Only one study has addressed
this issue, using amperometric recordings of quantal release to
midbrain DA neurons in culture [17]. Such recordings at high time
resolution (50 ms) show that although most DA release events are
“simple”, with a single classical spike, 15–20% consists of a rapid
succession of spikes that gradually decreases in amplitude from
ﬁrst to last. These “complex” events are consistent with ﬂickering
of the vesicle fusion pore, with each “ﬂicker” releasing 25–30% of
vesicular DA. The “simple” events had a similar quantal size as the
ﬁrst “ﬂicker” of a “complex” event suggesting that these two types
of events are variants of kiss-and-run [17]. The extent of fusion-
pore ﬂickering would impact the fraction of vesicular DA that is
released per fusion event (Fig. 1A). Complex events may allow
neurons to reuse vesicles rapidly without undergoing compara-
tively slow recycling. As complex events produce a higher quantal
size, complex events could regulate transmitter spillover.
Transient ﬂickering of the fusion pore occurs in adrenal
chromafﬁn and other large dense core vesicles [47,49] although
DA synaptic vesicle ﬂickers are considerably shorter (100–150 ms
vs. 10,000–500,000 ms respectively) and occur at a much higher
frequency than in dense-core vesicles (4000 Hz vs. 170 Hz) [49]
with a far greater fraction of transmitter released (25–30% vs.<1%)
[49]. Fusion pore ﬂickering is also seen at glutamatergic synapses
[50].
Andrew Ewing and colleagues developed a microﬂuidic-based
platform for catecholamine detection in isolated PC12 cell vesicles
and found that each vesicle released 40% of its total catechol-
amine load [51], consistent with kiss-and-run in these cells.The type of synaptic vesicle secretory event may be regulated by
protein kinase C (PKC) activity [17]. Drugs that enhance PKC
activity increase the number of events per stimulus but decrease
the fraction of complex events, whereas staurosporine, a broad
spectrum kinase inhibitor, decreases the number of events but
enhances the fraction of complex events. Most studies suggest a
negative regulation of kiss-and-run by PKC, including evidence
that pharmacological activation of PKC accelerates fusion pore
expansion and induces kiss-and-run to full fusion conversion
[52,53]. Conversely, PKC inhibition decreases fusion-pore size and
induces a switch from full fusion to kiss-and-run with higher
frequency stimulation [52]. PKC also contributes to full-fusion
exocytosis downstream of muscarinic ACh receptor (mAChR)
activation in chromafﬁn cells [54]. Interestingly, knockout or
inhibition of atypical PKC theta, but not the related atypical PKC
delta, decreases catecholamine quantal size [55], although
whether this is via vesicle fusion regulation remains unknown.
Fulop and Smith [52] suggest that increased ﬁring rates
enhance intracellular Ca2+ levels sufﬁcient to activate PKC, which
promotes fusion-pore dilation converting kiss-and-run events to
full vesicle collapse. Myosin II and the myristoylated alanine-rich
C-kinase substrate (MARCKS) are downstream of PKC in this
mechanism; PKC-induced phosphorylation of these proteins is
necessary to disrupt the actin cytoskeleton with high stimulation,
which appears to be crucial for the switch from kiss-and-run to full
fusion [56,57]. Myosin inhibition and the disruption of actin
polymerization can also slow fusion-pore expansion and increase
fusion-pore lifetime without affecting quantal size, suggesting
facilitation of catecholamine release from the vesicle by actin and
myosin [58].
In addition to ﬂickering modes and kiss-and-run mechanisms,
recycling of synaptic vesicle membrane may occur via “bulk
endocytosis” of the membranes of many synaptic vesicles [59] or
via smaller clathrin coated endosomal intermediates [60,61]. The
involvement of dynamin on vesicle retrieval following kiss-and-
run exocytosis has been demonstrated by several groups [62].
While kiss-and-run and full fusion both require dynamin for
vesicle retrieval, kiss-and-run appears to be independent of
clathrin-mediated endocytosis, as disruption of clathrin function
inhibits the slow endocytosis characteristic of full fusion, but not
kiss-and-run-associated rapid endocytosis [63,64]. Conﬁrmation
of a direct role for dynamin in kiss-and-run was obtained using
ﬂuorescence imaging of PC12 cell plasma-membrane lawns, in
which the retrieval of fusing granules by kiss-and-run was
monitored by uptake of ﬂuid phase markers [65]. Retrieved
granules were preferentially associated with dynamin, and granule
recapturing was inhibited by dynamin function disruption, which
may involve a dynamin-synaptophysin interaction that is promot-
ed by elevated Ca2+ [66,67]. A model of “ultra-fast” synaptic vesicle
membrane endocytic recycling independent of clathrin has also
been reported [68].
When synaptic vesicle membrane is ultimately sent for
degradation, this may occur by fusion of endosomal compartments
to autophagosomes, although small synaptic vesicles also appear
to sometimes be engulfed by presynaptic autophagosomes [69].
1.2. How much DA is in a synaptic vesicle?
The term “quantal size” for monoamine systems, which mostly
exert their effects via G-protein-coupled receptors, has come to
mean the number of molecules released during a quantal event
[19]. This is a different meaning than that of Katz et al., in which
quantal size is indicated by the ionotropic-receptor currents that
result from transmitter released during fusion of a single vesicle.
With the newly introduced approach of electrochemical cytom-
etry, however, DA synaptic vesicles can be isolated directly from
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as the membrane is lysed [70]. In axonal DA vesicles from healthy
mice, transmitter content is 30,000 DA molecules, which can be
modulated by amphetamine and L-DOPA (see Sections 1.2.2 and
1.2.5).
A variety of means to modify the quantal size of DA have been
identiﬁed (for review, see [19,71]). A long-standing parallel effort
by William Van der Kloot has elucidated presynaptic mechanisms
that regulate quantal size at the neuromuscular junction, and his
reviews, which predate use of amperometric quantal detection in
CNS cells, are highly recommended [72,73].
1.2.1. Altered free energy for vesicular DA sequestration
Secretory vesicles maintain high levels of monoamines against
a large concentration gradient [74,75]. In isolated chromafﬁn
granules, monoamines (A) distribute according to the electro-






¼ DCFRT þ 2DpH
In chromafﬁn granules, granule pH is often estimated to be
5.6, the cytosolic pH 7.2, and DC  + 80 mV. Assuming RT/
F = 59 mV, this indicates an equilibrium transvesicular catechol-
amine gradient of 36,000:1.
This relationship hints at multiple interventions that might
alter quantal size (Fig. 1B). In the next section, we will ﬁrst discuss
effects on the right hand side of the equation, the pH and electrical
gradients. Then, we will discuss effects of the left side of the
equation, the DA concentration gradient across the membrane.
1.2.2. Roles of pH, electrical gradients, and amphetamines on vesicular
dopamine uptake
The pH gradient of synaptic and secretory vesicles is provided
by the vacuolar H+-ATPase, which consists of V0 and V1 subunits
[76,77]. [Some data implicate the V0 domain in the process of
vesicle fusion as well [78,79].]
Determination of pH in small synaptic vesicles is not only
challenging, but an elusive concept: the compartment is so small,
typical values such as pH and voltage gradients do not clearly
describe their state. A synaptic vesicle in a DA neuron of diameter




pð2  106cmÞ3 ¼ 3:4  1017cm3
corresponding to 3 1019 synaptic vesicles/L. If each synaptic




¼ 5  105moles=L ¼ 50 mM
This would provide a pH = –log(H+) = 4.3! Even odder, as the log
of zero is undeﬁned, a synaptic vesicle with no free proton has no
pH value. Thus, it would seem that small synaptic vesicles shuttle
between no pH value and a value of 4.3 or smaller.
One means to estimate synaptic vesicle pH has been to examine
quenching of “synaptopHluorin”, originally an “ecliptic” ﬂuores-
cent pH sensitive (pKa 7.1) green ﬂuorescent protein (GFP) mutant
added to the luminal domain of synaptobrevin [80], and
subsequently to a luminal domain of VMAT2 [81]. The ﬂuorescence
is quenched by proton binding to the residue Tyr-66, which
eliminates absorption of 488 nm wavelength light. When a
membrane-permeable weak base like ammonia is applied, the
pH gradient collapses so that all pH values are “clamped” to that of
the extracellular milieu. If extracellular pH is more basic than thesynaptic vesicle, ammonia-collapse of the acidic synaptic-vesicle
gradient would enhance the ﬂuorescent signal: thus, titration of
signal by lowering extracellular pH in the presence of ammonia
should indicate synaptic vesicle pH from the point at which it
ceases to cause brightening.
A more useful approach is to expose synaptopHluorin-
expressing neuronal cultures to pH 7.4 media, and then add
saturating levels of ammonia. The fraction of neutral synapto-
pHluorin (i.e., ﬂuorescent) moiety at a pH value is calculated from a
version of the Henderson-Hasselbach equation, where at pH 7.4
Qþ ¼ 1
1 þ 10pKapH
  ¼ 1
1 þ 107:17:4
  ¼ 0:67
The level of ﬂuorescence increase, DF, due to ammonia indicates
the amount of synaptopHluorin that has been neutralized (DQ+),
and can indicate the charge of the vesicle synaptopHluorin (Q+i)
prior to alkalinization.








DF þ 1 
For DF of 9, Q+i = 0.67/(10) = 0.067, indicating that 6.7% of
vesicular synaptopHluorin was neutral/ﬂuorescent prior to alka-
linization. In a DA bouton, which has 80 synaptic vesicles (Daniel
Garton, Ciara Torres, D. Sulzer, unpublished EM data), this likely
represents signal from 6 vesicles. Placing this value into the





¼ 7:1 þ log :067=1:067Þð Þ10 ¼ pH 6:0
There are a variety of issues that complicate the use of
synaptopHluorin to estimate synaptic vesicle pH. In some cases, a
high level of synaptopHluorin can be present on the plasma
membrane [82], although this is less of an issue with the use of
VMAT2-pHluorin, introduced by Robert Edwards and colleagues
[81], which has far less plasma membrane localization. Another
challenge is that pHluorin probes are most sensitive near their pK
which is near 7, so that a change from pH 5.0 to 5.5, typical of large
dense core catecholamine secretory vesicles [83,84], would yield a
very small change in signal. Nevertheless, this approach has been
usedto determinea synaptic vesicle pH of 5.6 in culturedDA neurons
[85] and a pHof 5.8 in DA neuronsin Drosophila brain [86]. As already
noted, current data seem to indicate that in situ most synaptic
vesicles have an undeﬁneable pH value with no free proton, while a
minority contain one or very few protons with a pH of 4.3.
In principle, ratiometric pH probes could provide more accurate
pH measurements. There are ratiometric pHluorins [80] as well as
a new class of pH-sensitive ratiometric ﬂuorescent false neuro-
transmitters that are VMAT substrates and have preferable pKa
values in the 5–6 range. Ratiometric ﬂuorescent false neuro-
transmitters have been used to study exocytosis from DA axons, as
they become brighter when released to the neutral extracellular
medium [28]. However, they have been used to monitor pH
changes in large dense-core vesicles, such as those in PC12 cells,
which have a large enough volume to monitor the pH of an
individual vesicle optically. Interestingly, PC12 vesicles display a
broad pH distribution even within an individual cell, which centers
around pH 5.9 [87].
Despite the challenges in determining synaptic vesicle pH, the
proton gradient across the vesicle membrane is of fundamental
importance for its function. Exposure of isolated catecholamine
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redistributes transmitter from inside to outside the vesicle [74,88].
The importance of the vesicular proton gradient in determining
monoaminergic quantal size was demonstrated in chromafﬁn cells
using baﬁlomycin, a H+-ATPase inhibitor, which decreases
catecholamine quantal size [84,89].
Lipophilic weak bases such as chloroquine are distributed
across membranes according to the pH gradient [90]. As their
concentration becomes sufﬁciently high, they exceed the buffering
capacity of the vesicle interior and collapse the pH gradient,
leading to decreases in quantal size [25].
Amphetamine and its derivatives like methamphetamine are
weak base compounds that are the only widely used class of drugs
known to elicit transmitter release by a non-exocytic mechanism
[2]. As substrates for both DAT and VMAT [91,92], amphetamines
can be taken up to the cytosol and then sequestered in vesicles,
where they act to collapse the vesicular pH gradient [88]. In
PC12 cells, where the pH of individual large secretory vesicles can
be estimated, pH-responsive ﬂuorescent false neurotransmitters
conﬁrmed that high methamphetamine (100 mM for 4 min) rapidly
alkinalized the mean vesicular pH from 5.9 to 6.4 [87].
Due to this ability to collapse vesicular pH gradients, amphet-
amine provided a ﬁrst instance of pharmacological manipulation
of DA quantal size, as measured in PC12 cells [25]. Subsequent
work showed that two classes of DA vesicles present in the giant
DA neuron of Planorbis corneus were differentially depleted by
amphetamine [93]. In dopamine axons of the striatum, electro-
chemical recordings in acute striatal slices suggest similar actions
of amphetamine in intact tissue [94,95], although contradictory
ﬁndings have yet to be resolved. For example, Paul Garris and
colleagues have shown that amphetamines indeed can enhance
synaptic vesicle fusion in DA neurons in vivo, perhaps via a circuit
mechanism [96]. Moreover, some of the decrease in evoked DA
release may also be due to activation of a striatal circuit in the
striatum (Lizardi-Ortiz et al., ms. in preparation).
New work conﬁrms that while amphetamines indeed collapse
acidic gradients in DA synaptic vesicles in mammalian striatum
and in Drosophila brain, the net reverse transport of protons
through VMAT during vesicular amphetamine uptake plays a larger
role in the collapse than does a “weak base” action, in which
protons are buffered by intravesicular amphetamine [86,97]. In
striatal brain slices, 20 mM para-chloroamphetamine can release a
ﬂuorescent antipsychotic compound from synaptic vesicles;
however, this effect is blocked by a VMAT2 inhibitor, reserpine,
indicating a requirement for VMAT mediated-proton efﬂux.
Reserpine does not block such redistribution by a higher
concentration of para-chloroamphetamine (100 mM), however,
indicating that amphetamine concentration plays a role in these
mechanisms [97]. In Drosophila, reserpine prevents methamphet-
amine-induced loss of protons, while chloroquine, a non-VMAT
substrate weak base, is not prevented by reserpine. The toxin MPP+
and its derivatives that are non-protonable VMAT substrates also
collapse the pH in a reserpine-sensitive manner [86]. Together,
these ﬁndings are consistent with a requirement for a role for
VMAT uptake and net proton antiport in the amphetamine-
mediated collapse of proton gradients of small synaptic vesicles, at
least at lower drug concentrations. This may contrast with
amphetamine actions at isolated large dense-core catecholamine
vesicles, in which VMAT blockade by reserpine was ineffective in
blocking the pH collapse by amphetamine and several other drugs
throughout the ranges examined [88].
An unexpected effect of prolonged amphetamine or weak base
exposure, at least in adrenal chromafﬁn catecholamine vesicles, is
a delayed rebound hyperacidiﬁcation that eventually leads to an
enhanced quantal size [83]. Likewise, extensive depolarization also
acidiﬁes chromafﬁn vesicles [84] and increases quantal size[84,98], in tandem with a greater proportion of larger “active”
vesicles that contain a halo around the dense core [84,99] [see also
[89,100–102]]. The mechanisms underlying enhanced acidiﬁcation
with prolonged weak base exposure or stimulation are unknown,
but may involve Ca2+-dependent PKA and PKC effects on quantal
size and exocytosis [55,103] or roles for counterions including Cl
and glutamate [104] (see following section).
Antipsychotic drugs are also weak base compounds [105] that
can accumulate in dopaminergic and other synaptic vesicles [106],
although they are not thought to act as VMAT substrates [97]: as
they would be released during synaptic vesicle exocytosis, such
loading and release could be important for their temporal and
spatial effects on synaptic transmission. Their effects on quantal
size may be complex, as while they would compete with DA for
protons, they would also act on D2 receptors.
1.2.3. Roles of Cl, glutamate, and GABA
The vesicular Cl channel regulates the vesicular pH gradient
since the entry of Cl dissipates the developing electrical potential,
enabling the H+-ATPase to generate a larger H+ concentration
gradient [74]. Regulation of ionic conductances by Cl [107], and
TRP channels [108] across the synaptic vesicle also control net
accumulation of transmitter, by regulating the electrical gradient
[84,109,110]. The predominant chloride channel on synaptic
vesicles, ClC-3, has been suggested to operate as a Cl/H+
antiporter rather than as a classical Cl channel [111]. Since the
stoichiometry of ionic exchange for these carriers was proposed to
involve the transport of two Cl ions per each H+, and therefore the
net movement of 3 positive charges out of the vesicles, this would
promote a greater dissipation of the electrical gradient than of the
H+ concentration gradient, prompting the H+-ATPase to pump
more protons in (Fig.1B). A Cl channel inhibitor caused a small but
signiﬁcant inhibitory effect on quantal size [84], while ClC-
3 knockout mice display a drastic reduction in catecholamine
quantal size [112].
Glutamate may also act as a synaptic vesicle counterion for at
least some DA neurons that express the vesicular glutamate
transporter (VGLUT2) [113], leading to co-release of glutamate and
DA [114–118]. It has been suggested that glutamate might diminish
the voltage component of the free energy gradient allowing for
greater DA packaging [104] (Fig. 1B). Glutamate acidiﬁes vesicular
pH in VGLUT2-containing vesicles of the ventral striatum, even in
the presence of high physiological concentrations of Cl, suggest-
ing that Cl and glutamate play distinct roles in regulating
vesicular proton gradients [104], although this is controversial
[118].
Recently, GABA, which is electroneutral, has also emerged as a
potential co-transmitter in DA neurons [119–121], with loading of
GABA into DA vesicles in a VMAT2-dependent manner [119]
although evidence for this in isolated DA synaptic vesicles is
presently lacking. If there is indeed signiﬁcant accumulation of
GABA by VMAT2, GABA might compete with DA and thus decrease
DA packaging, in addition to any effects that occur on exocytosis
due to GABA corelease.
1.2.4. Intravesicular storage capacity
Accumulation of high DA concentrations inside synaptic or
secretory vesicles also depends on the storage capacity of the
vesicular lumen. DA-containing vesicles, particularly large dense-
core vesicles, contain a condensed matrix of transmitters, proteins
and other small molecules. Small synaptic vesicles that released
soluble contents during previous fusion still have strongly charged
residues, and display a condensed matrix when exposed to 5-
hydroxy-DA as a false transmitter. Components of this intravesicular
matrix in dense-core vesicles are granins: water-soluble glycopro-
teins including chromogranin A and B and secretogranins. DA
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excessive vesicle swelling while allowing more transmitter storage
[122]. Granins are found in endocrine and neuroendocrine cells from
which they are co-released with monoamines during exocytosis
[123,124]. In addition to regulating vesicular levels of transmitters,
these proteins (or their proteolytic cleavage products) are implicated
in dense-core vesicle formation, vesicular sequestration of Ca2+ and
modulation of exocytosis [123–126].
A role for chromogranins in maintaining high catecholamine
levels in secretory vesicles was shown using chromafﬁn cells from
chromogranin A and B single- and double-knockout mice
[127,128]. Although cytosolic catecholamine levels increased in
chromogranin single-knockout cells incubated with L-DOPA,
catecholamine secretion per vesicle did not increase, suggesting
saturation of vesicular catecholamine accumulation.
Upon exocytosis, DA and other monoamines dissociate from the
intravesicular matrix for release into the extracellular space, likely
via ion exchange [129]. Temperature, osmolarity, extracellular pH
and cations can regulate quantal size in chromafﬁn cells, probably
by modulating catecholamine degranulation, although the mech-
anisms involved are poorly understood [19,130–132].
1.2.5. L-DOPA and dopamine synthesis
Typically, synthesis of L-DOPA from tyrosine via TH provides the
rate-limiting step in catecholamine synthesis. Regulation of TH
appears to underlie the decreased quantal size mediated by D2 DA
autoreceptors in PC12 cells [133]: quinpirole, a D2 receptor agonist,
inhibits TH activity and decreases quantal size by 40–50%. L-DOPA
increases DA synthesis and quantal size in PC12 cells indepen-
dently of TH, and prevents the effect of quinpirole on DA quantal
size. The effect of D2 receptor activation to decrease quantal size is
likely mediated by decreasing TH afﬁnity for its cofactor
tetrahydropbiopterin (BH4) by blocking a cAMP-dependent path-
way that mediates TH phosphorylation [134–139].
More broadly, regulation of TH expression by transcription, RNA
stability, and translation is inﬂuenced by many factors [140–142].
In midbrain DA neurons, cAMP can induce translation of TH mRNA,
increasing TH protein and activity without altering TH mRNA levels
[143]. Post-translational modiﬁcation plays a key role in the
regulation of TH activity: TH phosphorylation, which involves
many steps [142], inﬂuences the afﬁnity of TH for BH4 and for
interactions with other regulatory proteins, each of which could
regulate quantal size.
As TH is rate-limiting, administration of its product, L-DOPA,
proved to be a successful clinical intervention for Parkinson’s
disease [144], with effects at the synaptic level [145]. The effects of
L-DOPA on DA release have been studied extensively in cultured
cells using amperometry. In primary cultures of murine substantia
nigra pars compacta (SNc) neurons, L-DOPA increases quantal size
by 300% (from 3,000 to 10,000 DA molecules) in only 30 min
[17,18], with a comparable increase in acutely dissociated DA
somata [20], retinal DA neurons [23], chromafﬁn cells [146] and
PC12 cells [84,147,148].
These effects on quantal size are consistent with in vivo FCV
data from the nucleus accumbens (NAc), in which L-DOPA leads to a
rapid increase in evoked DA release [149]. The ability of L-DOPA to
increase DA loading into synaptic vesicles in living animals was
shown by electrochemical cytometry [70]. In healthy mice, L-DOPA
(50 mg/kg administered 2 h prior to sacriﬁce) increased vesicular
DA storage by 240% (from 30,000 to 71,000 molecules). Although
absolute numbers vary with experimental paradigm L-DOPA
consistently increases vesicular DA content.
A surprising consequence of L-DOPA-mediated increase in
vesicular DA content is that it is accompanied by increased vesicle
volume [148], which helps compensate for the change in free
energy. Later capacitance recordings in cultured cells [146] andmeasurements of vesicles isolated from animals treated with L-
DOPA [51], suggest that increased vesicle volume results from the
fusion of additional membrane with the vesicles.
1.2.6. VMAT2 activity
VMAT expression levels further regulate DA accumulation. In
chromafﬁn vesicles, inhibition of the peripheral vesicular trans-
mitter, VMAT1, with reserpine decreases catecholamine content
[150,151], which is reﬂected in decreased quantal size detected
with amperometry [152]. Surprisingly, however, VMAT1 inhibition
by reserpine decreases the volume of dense-core vesicles (the
converse of the increase seen with L-DOPA), although the resulting
catecholamine concentration remains constant [84,99,146].
Expression of the CNS transporter isoform, VMAT2, in
hippocampal neurons facilitates secretion of presumed DA from
these normally non-DA cells in the presence of L-DOPA [22]. In
cultured DA neurons, overexpression of VMAT2 markedly
increases quantal size, and also increases the number of events
per stimulus, likely by revealing events that were otherwise buried
in the noise [153]. Interestingly, synaptic-vesicle recycling in DA
axons in VMAT2 knockout mice appears normal, suggesting that
recycling is independent of the rate of transmitter accumulation
[154].
It has been suggested that DA production and vesicular loading
are carried out by a complex of linked proteins [155–157] including
a direct interaction between the DA synthesis machinery and
VMAT [156], as TH and aromatic amino acid decarboxylase (AADC),
which converts L-DOPA to DA, co-immunoprecipitate with VMAT
from rat striatal lysates and PC12 cells. Uptake of DA into striatal
synaptic vesicles is decreased when interaction between VMAT2
with TH and AADC are disrupted [156]. Whether this also decreases
quantal size is unknown.
An essential role for vesicular catecholamine storage is
demonstrated by VMAT2 knockout mice, which die within days
after birth [158]. FCV recording in striatal slices from 2- to 4-day
old mice showed that DA release evoked by electrical stimulation
can be detected in wildtype but not VMAT2 knockout littermates
[157]. VMAT2-deﬁcient mice expressing only 5% of wildtype
VMAT2 levels, however, survive well into adulthood [159,160].
Consistent with the expected decrease vesicular DA stores, single
pulse-evoked DA release in slices of dorsolateral striatum from
these mice is only 30% of control [161].
VMAT is regulated at the levels of protein expression and post-
translational modiﬁcation. In chromafﬁn cells, an increase in
VMAT2 mRNA and protein occurs with long-term depolarization in
a Ca2+-dependent manner [162–164]. Among potential VMAT
regulators are G-proteins that inhibit VMAT-mediated uptake in a
variety of systems [71]. The G(o2) alpha protein, for example, can
associate with secretory vesicles, and inhibit the activity of VMAT1
and VMAT2 [71,165,166]. G(q) alpha inhibition of VMAT2 in mouse
platelet granules depends on luminal transmitter levels as it does
not occur in monoamine-depleted granules, and is restored upon
vesicle reﬁlling [167].
Pharmacological regulation of VMAT in vivo by DAT inhibitors
and amphetamine analogues also occurs through a mechanism
that involves D2 receptor activation [168]. DAT inhibition by
cocaine or methylphenidate in vivo induces a rapid increase in
vesicular DA uptake and in VMAT2 levels in puriﬁed striatal
vesicles from treated rats [169,170], apparently from redistribution
of VMAT2 within synaptic terminals [169] downstream of D2
activation [170–172]. In contrast to DAT inhibitors, methamphet-
amine and other amphetamine analogues decrease vesicular DA
uptake and VMAT2 levels in striatal vesicles, an effect that is
inhibited by D2 receptor antagonism [168,173].
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neuronal DA quantal size [18], although the mechanism remains
unknown. Emerging evidence suggests that brain-derived neuro-
trophic factor (BDNF) also regulates DA release. In transfected
hippocampal neurons, BDNF co-localizes with VMAT2 [22]. This
association appears to have functional consequences, with an age-
related decrease in VMAT2 and DAT activity in mice with partial
BDNF deletion (BDNF+/). An age-related decrease in evoked
striatal DA release and in motor performance is also seen in BDNF+/
mice [174,175], with partial restoration of electrically evoked DA
release in slices by exogenous BDNF [174,175].
1.3. Regulation of the number of synaptic vesicles that fuse
1.3.1. Ca2+ dependence of dopamine release
As introduced by Fatt and Katz [5] at the neuromuscular
junction, extracellular Ca2+ regulates quantal DA release from
axons and dendrites [176,177]. The voltage-gated Ca2+channels
that regulate striatal DA release have recently been re-character-
ized without the confounding inﬂuence of Ca2+ channels on
cholinergic interneurons (ChIs; see Section 1.4.1 and 1.4.4) that
were unavoidably included in previous studies. These include N, P/
Q, T and L-type Ca2+ channels [178], whose roles can vary with
ﬁring rate, due to Ca2+ effects on short-term plasticity. The relative
dominance of these Ca2+ channels also differs between dorsal
striatum (caudate-putamen, CPu) and ventral striatum (NAc), with
evidence for different Ca2+ microdomains and buffering between
these regions. A variety of heteroreceptors and the D2 autoreceptor
can also regulate Ca2+ currents in DA axons [179] (see Section 1.4.1).
The speciﬁc Ca2+ channels required for somatodendritic DA release
remain uncertain [180], given that the release can be triggered in
very low extracellular Ca2+ concentrations [181]; contributing
factors, including intracellular Ca2+ stores [182], are discussed
elsewhere [183].
1.3.2. Regulation of fusion modes by synaptic proteins
Mechanisms that might “overrule” control of fusion events by
Ca2+ include presynaptic proteins can block synaptic vesicle fusion,
like tomosyn [184], which has a synaptobrevin-like motif that may
compete with binding of synaptic vesicles via SNARE proteins
[185,186]. Through a completely different mechanism, fusion of
chromafﬁn dense-core vesicles is regulated by an adaptor protein,
AP-3 [187,188], with a decrease in quantal size associated with
over-expression of the neuronal isoform, and an increase in
quantal size with proportional changes in vesicle volume
associated with AMP-3 deﬁciency. Although AP-2 and AP-3 are
involved in synaptic vesicle recycling [189], effects on DA quantal
size are unreported.
Examination of evoked DA release in the striatum in vivo using
FCV in synapsin I/II/III triple knock-out mice suggests that these
proteins regulate DA synaptic vesicle “reserve pools” [190], and
that synapsin III might be particularly important for DA release
[191]. Another form of regulation is presynaptic macroautophagy.
Striatal DA boutons can form autophagic vacuoles that can
sequester and degrade synaptic vesicles, resulting in decreased
evoked DA release [69], for example when mTOR is inhibited in the
presynaptic bouton.
The most studied endogenous regulator of quantal DA release is
alpha-synuclein, a synaptic protein aggregated in Parkinson’s
disease that can inhibit DA release [192]. Inhibition of axonal DA
release by wild-type alpha-synuclein can be attenuated by activity
and elevated Ca2+ [192–195], possibly as Ca2+ elevation redis-
tributes alpha-synuclein away from synaptic vesicles [196]. In
chromafﬁn cells, this inhibitory effect occurs at a late pre-fusion
“priming” step [197]. Animals deﬁcient in combinations of alpha-,
beta- and/or gamma synuclein show more obvious effects on DArelease than single knockouts [198]. Conversely, transgenic rodent
lines overexpressing human wild-type alpha-synuclein, at levels
that approximate those following gene locus multiplication in PD,
show deﬁcits in DA transmission in dorsal but not ventral striatum
[199]. The A30P or A53T mutations appear to inhibit DA release,
consistent with gain-of-function mutations [193,194,200,201].
1.4. Regulation of axonal dopamine release by autoreceptors and
heteroreceptors
Modulation of axonal DA transmission can occur at the level of
midbrain DA cell bodies and locally at presynaptic axons. Here we
focus on regulation at the axonal level (see also [202,203]);
description of consequences of DA neuron activity on striatal
release can be found elsewhere [204–207]. A key regulator of
axonal DA release are D2 autoreceptors, which were identiﬁed on
DA axons using immuno-EM [208]. This method has also been
invaluable for identifying heteroreceptors on DA axons, including
GDNF receptors [209], b2-nicotinic ACh receptors (b2-nAChRs)
[210], delta and kappa opioid receptors [211,212], metabotropic
mGluR1 [213], and possibly GABAB receptors [214]. Although the
presence of other presynaptic receptors in DA axons remains to be
conﬁrmed, studies using synaptosome preparations, microdialysis,
and FCV data from in vivo and ex vivo slices suggest important roles
for heteroreceptor modulation on DA release, albeit with some
conﬂicting results.
1.4.1. Dopamine autoreceptors
There is a long history of examining the role of autoregulation of
DA neuron activity and DA release via DA receptors presumably
expressed on DA neurons and axonal release sites. Activation of
autoreceptors decreases release by mechanisms that include
inhibiting DA synthesis, enhancing DA uptake by DAT, and
regulating VMAT expression [215]. Here we focus on effects of
autoreceptor activation on release probability. Most of this work is
based on the assumption that the effects of DA on subsequent DA
release are mediated by autoreceptors on DA axons, but this has
been somewhat upended by studies suggesting that DA receptors
on other neurons, including medium spiny neurons and ChIs, also
regulate DA release [216,217].
D2 receptors are expressed along the somatodendritic extent of
midbrain DA neurons [208]. Roles for D2 autoreceptors in
presynaptic regulation are well established, but a role for
D3 autoreceptors has been controversial. D3 immunoreactivity
is found in most midbrain DA neurons, but is undetectable in
axonal regions [218]. While it has been suggested that both D2 and
D3 receptors function as autoreceptors [219–222], no deﬁcits in
autoreceptor function are apparent in D3-receptor knockout mice,
although extracellular DA concentration ([DA]o) in NAc is elevated
[223]. Conversely, D2-receptor knockout mice show no detectable
autoreceptor response to D2-family agonists on ﬁring rate, DA
release or DA synthesis. These results implicate the D2 receptor as
the primary functional autoreceptor [224–227].
Nevertheless, biphasic suppression of DA release monitored
using FCV in striatal slices is seen with a D3-selective agonist, 7-
OH-DPAT, which provides evidence for D3- as well as D2-
dependent DA release regulation [228]. This is supported by a
study in striatal slices from D3-KO mice that suggested some role
for D3 in regulation of secretion, but not synthesis [229].
D3 receptors can couple to the same G protein-activated inwardly
rectifying potassium channels (GIRKs) as D2 receptors [230–232],
and can thereby affect DA release [233], however, even in acutely
dissociated midbrain neurons from D2-knockout mice,
D3 receptor-activation of GIRK currents is absent [234].
In summary, DA autoreceptor function is predominantly carried
out by D2 receptors. It has been suggested that of two isoforms of
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serves presynaptic autoreceptor functions regulating DA release
while D2L acts mainly at postsynaptic sites [235–237].
Autoreceptor regulation of DA release was initially studied in
vitro with neurochemical approaches [238], and shown to inhibit
axonal [239–245] and somatodendritic DA release [241]. The
molecular mechanism underlying DA release inhibition through
axonal D2 autoreceptors is unresolved. The simplest explanation is
D2 receptor-dependent GIRK activation, with inhibition of DA
release caused by membrane hyperpolarization and current
shunting, as seen in DA neurons [246]. Consistent with this
mechanism, pulse-train evoked DA release in guinea-pig CPu is
enhanced by tertiapin, a GIRK channel blocker [247]. Caveats,
however, are that tertiapin has limited efﬁcacy at GIRK2 channels,
the primary subtype in mouse DA neurons [248], and additional
effects on cholinergic interneurons were not considered (see
Section 4). Adding further doubt to GIRK channel involvement in
D2-autoreceptor regulation of axonal DA release, FCV studies in
striatal slices suggest involvement of a very different class of K+
channels, speciﬁcally Kv1.2, 1.3 and 1.6 [Martel et al. [464]], which
are voltage-dependent rather than G-protein coupled channels.Fig. 2. Striatal cholinergic innervation of dopamine axons and the cholinergic receptor
(A) The striatum receives dense innervation from intrinsic cholinergic interneurons (ChIs)
Cre mice (courtesy of KA Jennings and SJ Cragg).
(B) Direct localization of b2-subunit-containing (b2*) nicotinic cholinergic receptors (n
(C) Cartoon of the range of subtypes of striatal nAChRs and muscarinic cholinergic recep
control of DA release by acetylcholine (Ach) in nucleus accumbens (NAc, left) and cauda
appear to operate in CPu than in NAc. M2 and M4 mAChRs regulate dopamine by reguAdditionally, D2 autoreceptor activation can inhibit voltage-
gated Ca2+ channel opening: patch clamp studies using dissociated
midbrain DA neurons show that D2 receptor activation decreases
Ca2+ currents primarily via N- and P-type Ca2+ channels [179]. As
axonal DA release is supported by at least N- and P/Q-type Ca2+
channels [177,178,180,249], inhibition of Ca2+ channels could
contribute to DA release inhibition. Direct D2 regulation of Ca2+
channels has not been proven, although K+ channel activation
would decrease voltage-dependent Ca2+ currents. Further muddy-
ing the waters, autapses (synapses that a neuron makes on itself) of
cultured midbrain neurons show no evidence of D2-autoreceptor
regulation of Ca2+ inﬂux [250].
Regulation of DA release by autoreceptors in vivo was ﬁrst
shown using microdialysis. Striatal [DA]o increases with systemic
or intra-striatal administration of D2 antagonists, and decreases
with intra-striatal infusion of a D2 agonist [251]. In vivo
electrochemical studies indicate that basal [DA]o is sufﬁcient for
tonic stimulation of D2 autoreceptors, and inhibition of action
potential-dependent DA release [252,253]. Mice lacking
D2 receptors allowed evaluation of dynamic autoreceptor regula-
tion [224]. As in similar studies in rodents and primates subtypes involved.
, shown by green ﬂuorescence after injection of eYFP-containing constructs in ChAT-
AChRs) (arrows) on dopamine (DA) axons, reproduced from [210] with permission.
otors (mAChRs) and their locations on ChIs or DA axons that appear to govern the
te-putamen (CPu, right). A broader range of nAChR and mAChR types (color-coded)
lating ChIs, whereas M5 mAChRs regulate DA release directly.
132 D. Sulzer et al. / Basal Ganglia 6 (2016) 123–148[227,254,255], a conditioning electrical stimulus was given, and
the effect on a test pulse assessed at varying times afterwards. In
control mice, the onset of the D2-mediated inhibition of DA release
is 50–100 ms, with a maximum effect 150–300 ms after the
conditioning stimulus, and termination by 800 ms; this regulation
was lost in D2 knockout mice [224]. Similar kinetics occur in ex vivo
slices, with a maximum 500 ms and a duration <5 s. The slightly
longer time course in slice studies may reﬂect larger evoked DA
concentrations and/or lower temperatures used.Fig. 3. Acetylcholine ﬁlters and drives dopamine transmission.
(A) Cartoon of the effects of cholinergic interneuron (ChI) activity on dopamine (DA) relea
“on” (activated), DA release level only weakly reﬂects frequency of activity in DA neuro
dashed line: When nAChRs are “off”, e.g., during ChI pause or after desensitization by ni
effects of other inputs could be mediated via ChIs (e.g.,left) or be direct on DA axons (e
(B) Light-activation of ChR2-expressing ChIs in striatum generates single action potenti
permission from [290].1.4.2. Glutamate
Although microdialysis studies suggest a stimulatory effect of
ionotropic glutamate receptor activation on striatal DA release, FCV
recordings show an inhibitory role [256–258]. The effects of
ionotropic glutamate-receptor activation on DA release are most
likely indirect given that DA terminals are generally thought to lack
these receptors [259,260]. Studies by Margaret Rice’s group
suggest that glutamatergic regulation of DA release in CPu is
indirect and mediated by AMPA receptors on striatal medium spiny
neurons, as reviewed elsewhere [183,261]. Brieﬂy, AMPA receptor-se. Left of dashed line: When nicotinic cholinergic receptors (nAChRs) nAChRs on are
ns or ChIs. Other inputs can regulate DA release by regulating ACh release. Right of
cotine, DA release better reﬂects frequency of activity in DA neurons. Note that the
.g., right), but in either case could depend on activity in ChIs.
als in individual ChIs and directly drives large DA release events. Reproduced with
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chondrial H2O2 generation [262]. Membrane permeable H2O2 then
leaves the generating cell to inhibit DA release from adjacent DA
axons [247,263]. Inhibition of DA release by H2O2 is mediated by
ATP-sensitive K+ (KATP) channels on DA axons [247,264]. Regulation
of axonal DA release by H2O2 is rapid and transient, like that of
D2 autoreceptor-dependent inhibition, with signiﬁcant suppres-
sion 500–1000 ms after stimulation [264]. Notably, most studies of
AMPA receptor/H2O2 modulation of DA release were conducted in
guinea-pig striatal slices using FCV. Although endogenous H2O2
also suppresses evoked DA release in rat striatum in vivo [265], this
modulation may differ in other species, including mice [183].
Another indirect means of glutamatergic regulation of DA release
in striatum is via effects on ChIs, which powerfully regulate DA
release (see Section 1.4.4).
In contrast to ionotropic glutamate receptors, a metabotropic
glutamate receptor, mGluR1, has been detected by immuno-EM on
striatal DA axons [266], and evoked DA release can be inhibited via
mGluR1 [267].
1.4.3. GABA
Microdialysis data support an inﬂuence of GABA on DA release
via presynaptic GABAB receptors in rats [268], consistent with
some limited ultrastructural evidence in monkey for GABAB
receptors on DA-like axons [214]. In FCV recordings in mouse
striatal slices, GABAB receptor agonists inhibit single-pulse evoked
release in CPu and NAc with kinetic parameters similar to those of
D2 autoreceptors [227,269]. In guinea pig or mouse striatal slices,
however, GABAB receptor antagonism has no effect on single-pulse
or pulse-train evoked DA release [256,270].
Modulation by GABAA receptors seem to be postsynaptic and
mediated by striatal interneurons [268]. Muscimol, a GABAA
agonist, inhibits evoked DA release in striatal synaptosomes [271]
and also inhibits evoked DA release by single-pulse stimulation in
striatal slices (Zhang and Sulzer, unpublished). The circuitry
responsible remains unresolved, but could for example involve
ACh (see Section 4). Conversely, pulse-train-evoked DA release in
slices of guinea pig CPu is suppressed when GABAA receptors are
blocked, implying a normally enhancing role for endogenous GABA
[256]. This is mediated by the inhibitory intermediate, H2O2
generated downstream from AMPA receptor activation: the effect
of GABAA antagonism is lost in the presence of catalase, an H2O2
metabolizing enzyme, or when AMPA receptors are blocked (see
[261]).
1.4.4. Acetylcholine
ACh plays a dominant role in shaping DA release probability and
its dynamic short-term plasticity through action at nAChRs and
mAChRs. nAChRs are expressed densely on DA axons throughout
the dorsal and ventral striatum [272,273]. Rodent SNc and ventral
tegmental area (VTA) DA neurons express mRNAs for nAChR
subunits a3-7 and b2-4 [274] and DA axons have diverse subtypes
of heteropentameric b2-subunit-containing (b2*) nAChRs [275–
278]. FCV studies using an a6-speciﬁc antagonist and subunit-
speciﬁc knockout mice indicate that the nAChRs subtypes
regulating DA release are a4a5b2 and a6b2b3 in CPu but
a4a6b2b3 in NAc [277–281] (Fig. 2). Non-b2*-nAChRs, i.e.,
homomeric a7-nAChRs, have not been identiﬁed on DA axons;
however. a7-nAChRs can regulate evoked striatal [3H]-DA release
indirectly via nAChRs on glutamate terminals [282].
Recent slice FCV studies have revised the view of presynaptic
nAChRs on DA axons. First, these nAChRs can modulate or ﬁlter
how action potentials in DA neurons are translated into DA release
(Fig. 3). When nAChRs are antagonized, DA release evoked by local
single-pulse or low-frequency pulse-train stimulation is sup-
pressed [283–285] indicating that local ACh acting at nAChRs isexcitatory. Without nAChR activation, however, the short-term
depression that normally limits subsequent release of DA is
relieved, facilitating release; moreover, the shorter the inter-pulse
interval in a train (higher frequency), the greater the short-term
facilitation of release. Release by high-frequency activity when
nAChRs are off can exceed that when on. Changes in frequency
dependence are also seen after knockout of speciﬁc nAChRs or
deletion of forebrain ACh from striatal ChIs [286]. Thus, pauses in
ChIs may allow more faithful translation of action potentials into
DA release, and enhance signal gain. Nicotine, a nAChR agonist,
rapidly desensitizes striatal nAChRs, and has the same outcome as
turning nAChRs off by an antagonist [283–285]. In vivo, systemic
nicotine enhances [DA]o detected by microdialysis [287] and, like
cocaine and alcohol, increases the frequency of DA transients in
NAc [288]. These powerful effects of ACh on DA release could
participate in the effects of many other striatal modulators that act
on striatal ChIs (Fig. 3A, left), or could inﬂuence whether or not
effects of other modulators acting directly (Fig. 3A, right) can be
seen (Brimblecombe and Cragg, unpublished observations).
The combination of FCV with optogenetics and patch-clamp
recordings indicates that synchronized action potentials in a small
network of striatal ChIs activates nAChRs and drives axonal DA
release in ex vivo slices and in vivo [289,290], bypassing action
potential generation in midbrain (Fig. 3B). DA release can be driven
by nAChRs in response to direct ChI activation or indirect ChI
activation by optogenetic stimulation of glutamatergic inputs (e.g.,
from thalamus) [290]. Amperometric studies with millisecond
time resolution [291], as well as electrophysiological studies using
expression of a DA-activated ion channel [26], indicate that local
electrical stimulation ﬁrst drives a DA release event by direct
depolarization of DA axons, which summates with a second DA
release event several milliseconds later driven by ACh release from
ChIs. This contributes to nAChR-dependent modulation of DA
release and its subsequent depression. Nicotine turns off ChI-
driven DA release [290,291], which may contribute to the
enhancement of reinforcement by nicotine.
The striatum shows dense expression of mAChRs, with
evidence for tonic DA release inhibition by mAChRs in human
imaging studies [292]. Pharmacological studies of mAChR effects
on DA release in rodents have been contradictory, however, in part
because of the limited subtype selectivity of available ligands
[293–301]. DA neurons express only M5 mAChRs [302,303], but the
use of mice lacking M1–M5 mAChRs indicates that different
subtypes mediate facilitation (M4/5) versus inhibition (M3) of DA
release, with some receptors acting via modulation of striatal GABA
at GABAA receptors [304], presumably indirectly given the
apparent absence of GABAA receptors on DA axons.
Key controversies in this area have been resolved using FCV in
striatal slices [270], which showed that a key action of mAChRs is
to regulate ACh release, which then acts at nAChRs on DA axons to
modulate DA release (see Fig. 2). The broad-spectrum mAChR
agonist, oxotremorine, decreases single-pulse or low-frequency
evoked DA release, but relieves short-term depression, allowing
enhanced release by longer or higher-frequency trains. This effect
was identical to, substituted for, and was prevented by prior
application of nAChR antagonists. Thus, activation of mAChRs on
ChIs, which inhibits their ﬁring [305], inhibits ACh release and
nAChR activation. Experiments in subtype-speciﬁc knockout mice
implicated M4-mAChRs in NAc, but M2- and M4-mAChRs in CPu
[270] (Fig. 2). This regional distinction was surprising, but broadly
consistent with the expression of M2/M4-family by cholinergic
interneurons [306,307].
The role of M5-mAChRs has been reﬁned further: M5-mAChRs
are expressed by DA neurons but have not been localized on DA
axons [308]. M5 knockout mice (M5-KO) show decreased DA
release [309], but the effects of mAChR agonists on frequency
Fig. 4. Neuropeptide regulation of DA release.
(A) Upper left, Substance P enhances, diminishes, or has no effect on DA release depending on position within striosome-boundary-matrix compartments, identiﬁed by
distance of recording site to nearest striosome edge (d1). Upper right, patchy striosomes are indicated by mu-opioid-receptor immunoreactivity (MOR-ir). Lower panels, show
typical carbon-ﬁbre microelectrode recordings sites (marked with yellow Fluosphere beads within green circles, 25 mm radius) within striosomes (S), on the boundary with
matrix (M), and within matrix. Scale bars 100, 200, 1000 mm as indicated. Adapted with permission [249].
(B) Upper left, insulin (Ins) increases DA release in rat NAc shell, NAc core, and CPu; average single-pulse evoked [DA]o before and after Ins (30 nM); error bars omitted,
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role for M5-mAChRs on DA axons [304] (Fig. 2). Recent studies in
mice with conditional M5-mAChR deletion in DA neurons conﬁrm
that M5Rs on DA axons promote DA release [310].
1.4.5. Opioids
Kappa-opioid and delta receptors are located on DA axons [211]
whereas mu-opioid receptors are not [311]. Schlosser et al. [312]
ﬁrst demonstrated that mu, delta, and kappa receptors inhibit DA
release in striatal slices. The key role of ACh in regulating DA
release also explains the ﬁnding that activation of mu-opioid
receptors in NAc shell, which can inhibit ChIs, decreases DA release
driven by single-pulse but not pulse-train stimulation [313]. Thus,
the effect of kappa opioid receptors on DA overﬂow is likely to be
direct, whereas the inﬂuence of mu opioid receptors is indirect,
mediated by an inhibition of ChIs [211,313]. Whether the effect of
delta opioid receptors on DA release is direct remains unclear.
1.4.6. Neuropeptides: Substance P, insulin, growth factors, and CRF
Neurokinin-1 receptors (NK1Rs) for substance P (SP) are
expressed by DA neurons [314], although whether they trafﬁc to
axons is unresolved. In striatum, SP is released by D1R-expressing
neurons and is enriched within striatal compartments termed
striosomes. Slice FCV studies show that SP acting at NK1Rs
modulates DA release in a manner that varies with striosome-
matrix location [249]: SP enhances DA transmission within
striosomes at the expense of DA transmission at striosomes-
matrix borders, with no effect in the surrounding matrix (Fig. 4A).
These ﬁndings resolve previous contradictory reports about SP, and
reveal that mechanisms that regulate DA can vary between the
striosome and matrix compartments. The extent of DA release
regulation by striosomes-matrix compartmental enrichment of
other modulators and receptors [315], including mu-opioid
receptors, is unknown but may provide an important process in
the regulation of DA release and basal ganglia function. The recent
generation of new transgenic animals providing identiﬁcation of
striosomes versus matrix will aid future work in this area.
Insulin receptors (InsRs) are expressed widely in the brain,
including the striatum, with particularly high levels in the NAc
[316] and on DA neurons in the VTA and SNc [317]. In contrast to SP
and other neuroactive peptides discussed in this section, brain
insulin is derived primarily from pancreatic b-cells in the
periphery, rather than arising locally. Insulin acting at InsRs can
promote an increase in DA uptake via the DAT in a PI3 kinase-
dependent manner in the striatum [318,319] and in the VTA [320].
In the VTA, increased uptake is the predominant effect, so that the
net effect of insulin is to decrease evoked [DA]o monitored using
FCV in midbrain slices. This acute effect of insulin is augmented by
the induction of long-term depression of VTA neurons via
endocannabinoids [321].
In striking contrast, FCV studies in striatal slices show that the
net effect of insulin throughout the striatum is to increase evoked
[DA]o (Fig. 4B), despite a simultaneous increase in DAT-dependent
uptake, indicating a potent enhancement of DA release [319]. This
insulin-dependent enhancement is InsR and PI3- kinase depen-
dent, and occurs at physiological insulin concentrations (low nM)
(Fig. 4B). Companion immunohistochemical studies demonstrate
the presence of InsRs not only on striatal DA axons, but also on ChIs
(Fig. 4B). Consistent with the dominant role of ACh in shaping DA***p < 0.001. Upper right, representative recordings of peak evoked [DA]o vs. time at a sin
insulin (30 nM), or when insulin was applied in the presence of an InsR inhibitor, HNMP
acetyltransferase (ChAT), and insulin receptor (InsR); merged shows InsR expression on 
and after insulin (30 nM) in the presence of an nAChR antagonist, mecamylamine (Mec; 5
right, Single-pulse evoked [DA]o in ex vivo slices from heterozygous control (Het) and Ch
(**p < 0.01, ***p < 0.001 vs. control), but had no effect on evoked [DA]o in any striatal srelease dynamics, the enhancing effect of insulin on evoked [DA]o
was shown to require nAChRs and ACh: the effect of insulin is
blocked by nAChR antagonists and is absent in choline acetyl-
transferase (ChAT) knockout mice (Fig. 4B). These data suggest that
in addition to the established role of insulin as a satiety signal,
insulin may also signal reward. Indeed, behavioral tests using a
ﬂavor preference paradigm in behaving animals indicate that
insulin in the NAc shell inﬂuences food preference [319]. This not
only implicates insulin in food-related learning, but also conﬁrms
its role as a reward signal.
The trophic factor BDNF acts at TrkB (and P75) receptors.
Paradoxically, genetic deletion of brain BDNF leads to an increase
in striatal DA content, but lower evoked [DA]o in striatal slices that
is independent of changes in DA uptake [322]. The same pattern of
increased DA content and decreased DA release is seen in
heterozygous BDNF mutant mice (BDNF/+) [175,323]. These data
imply a role for BDNF in dynamic regulation of DA release. In line
with this hypothesis, exogenous BDNF enhances depolarization
evoked [3H]DA overﬂow from rat striatal tissue [324], and can
partially restore suppressed electrically evoked [DA]o in BDNF/+
mice [175].
The trophic factor GDNF, which acts at its canonical receptor
Ret, can also regulate striatal DA release and uptake. Through its
downstream signaling pathway, GDNF plays a key role in the
development, maintenance, and regeneration of the mesostriatal
DA system (for review, see [325]). In vivo electrochemical studies in
rhesus monkeys show an increase in K+-evoked DA release in the
CPu, three weeks after a single, ipsilateral GDNF injection in the
SNc [326]. Subsequent studies in rodents showed that intrastriatal
infusion of GDNF causes a long lasting increase in TH phosphory-
lation and presumed DA synthesis in striatum and SNc [327]. As
discussed in Section 1.2.6, GDNF increases quantal size for DA
release from axonal varicosities of midbrain DA neurons in culture,
and is the only growth factor that does so [18]. Recent studies using
genetic ampliﬁcation of GDNF levels with spatially unchanged
localization [328] show that GDNF increases DA neuron number in
midbrain and terminals in striatum, and increases DA content;
unsurprisingly, striatal DA release and uptake are increased in
these mice [328]. The role of GDNF and Ret signaling does not end
there, as GDNF acting via Ret also regulates DAT surface expression
through a signaling cascade that involves the Rho-family guanine
nucleotide exchange factor protein, Vav2 [329]. Mice deﬁcient in
either Vav2 or Ret have elevated DAT activity in the NAc, suggesting
that GDNF is a key determinant of DAT trafﬁcking in vivo and
contributes to DA homeostasis [329].
Corticotropin-releasing factor (CRF), a neuropeptide released in
response to acute stressors, acts at the CRF receptors CRFR1 and
CRFR2 and is associated with physiological and behavioral
responses to stress. Both acute and chronic antagonism of
CRFR1 decrease cocaine-stimulated DA overﬂow in the NAc; this
is correlated with an attenuation of cocaine-induced inhibition of
DA neuron activity from D2 autoreceptor activation by elevated
[DA]o [330]. Such data provide insight into the observation that
CRFR1 antagonists decrease cocaine self-administration and
inhibit stress-induced reinstatement of cocaine-seeking behavior.
Ex vivo slice studies show that application of exogenous CRF (10–
1000 nM) to the NAc iincreases DA release through co-activation of
CRFR1 and CRFR2 [331]. Severe stress in vivo abolishes the
enhancing effect of CRF on NAc DA release in slices for at leastgle site in NAc core in the absence of drug application (Con), during application of
A (5 mM). Middle, striatal ChI ﬁlled with biocytin, then immunolabeled for choline
ChIs; scale bar is 10 mm. Lower left, Single-pulse evoked [DA]o in rat NAc core before
 mM) or DHbE (1 mM), normalized to 100% peak control (p > 0.05 vs. control). Lower
AT KO mice before and after insulin (30 nM). Insulin increases evoked [DA]o in Hets
ubregion of ChAT KO mice (P > 0.1). Adapted with permission [319].
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can promote the onset of major depressive disorder in which an
acute stressor is no longer perceived as motivational, but rather
seen as an insurmountable impediment. Interestingly, loss of CRF
regulation of DA release is accompanied by a switch in the
response to CRF from appetitive to aversive [331], indicating the
crucial role of both CRF and DA in the emotional response to acute
stressors.
1.4.7. Adenosine
Evidence for presynaptic localization of A1 receptors on DA
axons is indirect [332–334], with conﬁrmed absence of A2A
receptors [335,336]. Nevertheless, both regulate striatal DA
release, likely indirectly, with inhibition by A1-receptor activation
[337,338] and enhancement by A2A-receptor activation [339].
1.4.8. Cannabinoids and others modulators
FCV studies in CPu indicate a lack of direct DA release regulation
by cannabinoid receptors (CB1Rs) [267,340,341], consistent with
anatomical evidence for the absence of CB1Rs on DA axons [342–
344]. Nevertheless, cannabinoids do inﬂuence striatal DA release
(for review see [345]). In rat striatum in vivo, CB1 agonist
administration decreases evoked DA release, while increasing
the frequency of spontaneous DA transients that presumably
reﬂect effects on neuronal ﬁring [346]. In striatal slices, CB1R
activation suppresses pulse-train evoked DA release, but has no
effect on single-pulse evoked release, suggesting an indirect effect
[341]. Additional evidence supports a role for local circuit
interactions involving inhibition of GABA release, consequently
enhanced generation of H2O2, and activation of KATP channels to
inhibit DA release [341]. Additionally, midbrain VTA DA neurons
produce cannabinoids [347–349], that activate local receptors that
regulate DA neuron activity and shape NAc reward encoding [350].
Other candidate neuromodulators in striatum might modulate
DA release via heteroreceptors on DA axons or their inputs, as well
as without classic plasma membrane receptors. For example, nitric
oxide (NO) can act directly at DA axons to enhance DA signals, and
indirectly via local circuits particularly ChIs to modify frequency
dependence [351]. In vivo evidence suggests that NO can also
enhance DA levels by inhibiting the DAT [352].
1.5. Relationship between ﬁring and vesicular release
1.5.1. Frequency dependent modulation of dopamine release
The studies summarized in Sections 1.4.2–1.4.8 demonstrate
heteroreceptor regulation of DA release, despite some inconsis-
tencies that reﬂect differences in stimulation and recording
paradigms, preparations, and species. Some conﬂicting results
have been reconciled following identiﬁcation of the key role of ACh
from ChIs, which can have bidirectional effects on DA release,
depending on the frequency of activation. Decreased ACh input can
decrease DA release probability, leading to low release evoked by a
single stimulus or low-frequency train; this leaves more DA for
release by subsequent pulses, especially at higher frequencies, thus
amplifying the frequency dependence of release [284,285]. The
outcome of heteroceptor modulation of DA release will therefore
depend on the protocol used to drive DA release.
There are known differences between striatal DA release in
slices, in which local stimulation produces paired-pulse depres-
sion, and in vivo, in which medial forebrain bundle-evoked DA
release shows no depression. A key difference is that local electrical
stimulation not only generates action potential dependent DA
release, but also recruits ChIs [290], which profoundly increases DA
release probability and subsequent depression of release, as
already discussed. In addition, neither in vivo or ex vivo slice
experiments can exclude wider circuit effects on other striatalcircuitry, or additive effects on inputs to DA somata and dendrites
in vivo.
A good example of complex effects is seen with systemic
nicotine administration. Nicotine at levels experienced by smokers
(250–300 nM) desensitizes nAChRs, which potently inhibits
striatal DA release evoked by single-pulse or low-frequency
stimulation, but enhances the frequency dependence of DA release
[284,285] (Fig. 2). In concert with increases in DA-neuron ﬁring
frequency and burst-ﬁring from activation of nAChRs in VTA and
SNc [204,280,353], this leads to enhanced phasic vs. tonic DA
signals, and also a net increase in striatal [DA]o, monitored by
microdialysis [287]. Nicotine thus enhances the contrast of DA
signals associated with reward-related cues processed by DA
neurons [284,285]. These effects also explain previous reports that
dismissed striatal nAChRs as a site of nicotine action because intra-
striatal nAChR antagonist administration did not prevent effects of
systemic nicotine on striatal DA levels [354,355].
1.5.2. Silent dopamine release sites?
In the sympathetic nervous system, release of noradrenaline
exhibits low release probability per site (about 1%) [356,357]. An
initial study using ﬂuorescent false neurotransmitters (FFNs),
which are ﬂuorescent VMAT2 substrates, indicates that the fraction
of total presynaptic DA released per action potential in striatum is
even less than 1% and is regulated by the frequency of activity [29].
Recent data are consistent with a high fraction of presynaptically
silent release sites that contain synaptic vesicles, even with high
levels of Ca2+ entry as shown by simultaneous imaging with a
GCaMP Ca2+ indicator [30].
2. Dopamine uptake
During the 1960s it was shown that DA neurons express DAT,
which was later conﬁrmed to be densely and speciﬁcally localized
on DA cell bodies and axons [358,359]. Given this discrete
localization, it was hypothesized that the DAT might control the
intensity and duration of DA transmission [360]. Microdialysis and
voltammetric techniques enabled monitoring [DA]o in vivo. Both
approaches showed that under resting conditions, [DA]o is low
(10–20 nM) and that DA uptake strongly contributes to DA
clearance after release. Indeed, pharmacological inhibition of DA
uptake by drugs like cocaine potently enhance [DA]o [361,362] in
an activity-dependent manner, indicated by the loss of effect when
impulse-ﬂow dependent DA release is blocked [363].
Early voltammetric and microdialysis methods could not
provide an accurate description of the kinetics of DA clearance
because they could not distinguish between increased release and
decreased DA clearance, either of which would increase [DA]o. This
limitation was resolved with improvements in voltammetric
techniques, and new methods to ﬁt evoked increases in [DA]o
that allowed independent extraction of uptake and release terms
[364,365].
The development of mice lacking DAT (DAT/) [366] allowed
the relative contribution of DA uptake to DA clearance vs.
extracellular degradation, non-neuronal uptake, and diffusion to
be elucidated. In DAT/ mice, striatal DA content and TH levels
are decreased by 90%; paradoxically, however, DA synthesis rate by
TH is doubled, with a further decrease in DA content when TH is
inhibited [367]. Peak evoked [DA]o in striatal slices from DAT/
mice is decreased by 75%, despite the absence of competing DA
clearance by uptake [367]. Similarly, evoked [DA]o in vivo is
decreased by >90% in the dorsal striatum and by >80% in NAc in
DAT/ vs. DAT+/+, with a rapid and near complete loss of DA
release in DAT/ after inhibition of DA synthesis by TH [368].
These observations show that in striatum, recycling of released DA
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DA.
2.1. Kinetics of dopamine uptake
Electrical stimulation of DA axons induces brief DA overﬂow
that can be detected with rapid electrochemical techniques in vitro
[95] and in vivo [149,365]. The decay phase of evoked DA overﬂow
reﬂects the clearance of released DA, with an assumption of little
diffusional component because of the relatively uniform increase
in [DA]o in a given volume of stimulated striatal tissue. DA uptake
inhibitors slow the clearance rate by one order of magnitude
[95,149,369]. However, in DAT/ mice the decay phase is slowed
by two orders of magnitude, both in vitro [366,367] and in vivo
[368]. We and others have developed mathematical means to
determine the Km and Vmax values of DAT from the decay phase,
using modiﬁed versions of random walks [95] [tutorials on
conducting these analyses are at sulzerlab.org]
Inhibition of enzymatic DA degradation does not slow the decay
phase in the striatum of DAT/ mice in vitro. Inhibition of
monoamine oxidase in vivo, however, slows the decay phase in
DAT/, but not WT mice [367,368]. Therefore, in the intact
striatum, DA uptake represents the primary mechanism responsi-
ble for the clearance of uniformly released DA, with comparatively
negligible roles for extracellular DA degradation and non-neuronal
uptake. In DAT/ mice, DA clearance is mainly due to DA diffusion
[367,368]. Diffusion also plays a role in decreasing [DA]o
immediately near a release site under normal conditions [370,371].
In brain structures with weak DA innervation, including
amygdala, globus pallidus, prefrontal cortex and cingulate cortex,
DA clearance rates are much slower than in striatum, with half-
lives for evoked [DA]o of 2 s in these structures vs. 60 ms in
striatum [372]. In these regions, DAT inhibitors are less effective in
slowing DA clearance than in striatum [373,374]. Notably, in
prefrontal and cingulate cortex, hippocampus, and VTA, DA is also
cleared by the norepinephrine transporter [374–376].
Regulation of DA release and uptake is altered in parkinsonian
striatum [145]. Interestingly, the parallel loss of DA release and
uptake sites can allow for a similar net steady-state levels of
evoked [DA]o in vivo across a range of levels of DA depletion
induced by 6-OHDA, and also in striatum after DA axon
reinstatement by neuronal transplantation [377], which led
Bergstrom and Garris to propose the notion of passive stabilization
[378]. Nevertheless, the overall decrease in DAT activity in lesioned
striatum increases reliance on DA synthesis (as in DAT/ mice),
which contributes to the efﬁcacy of DA replacement by L-DOPA
[145], along with changes in DA release probability [379].
Following exocytosis, DA clearance from the extracellular space
is achieved by DAT. In addition to being important for shaping the
time frame, spatial constraints and the signal-to-noise ratio of DA
neurotransmission [19,215,371], recycling DA back into DA axons
provides a synthesis-independent mechanism to reﬁll vesicles.
DAT can therefore play an important role in regulating quantal size
by affecting presynaptic DA levels during neuronal activity. Indeed,
DAT inhibition by cocaine in PC12 cells causes a concentration-
dependent decrease DA released per quantal event [380]. Evoked
striatal DA release can also be decreased by sufﬁciently high
concentrations of cocaine and methylphenidate [381]. In
PC12 cells, this is not due to an inhibitory effect of
D2 autoreceptor activation on quantal size from elevated [DA]o,
as the effect of cocaine is unaltered by sulpiride, a D2-receptor
antagonist [382]. A possible weak base effect of cocaine on the pH
gradient of synaptic vesicles was also ruled out since amfonelic
acid, a DAT inhibitor that is not a weak base, mimicked cocaine’s
inhibitory effect on quantal size [133].A role for DAT in the regulation of DA quantal size was
conﬁrmed in DAT/ mice. As discussed, evoked striatal DA
release is markedly decreased in in vivo and in acute slices
[367,368]. Given the absence of anatomical abnormalities in
striatal DA release sites in these animals [383], the decreased
release is likely linked to the dramatic decrease in intracellular DA
storage. These studies, together with PC12 cell data, suggest that
the vesicular DA stores are regulated by DAT functionality.
A further role for DAT has also been proposed in the regulation
of mobility of vesicle pools for release. Cocaine and other DAT
inhibitors can increase DA release in a DAT- and synapsin-
dependent manner [190,191] consistent with mobilization of the
vesicle pool, and with a normal function for DAT in restricting pool
mobility and/or releasability.
2.2. DAT regulation
DAT expression can be affected by many factors, including DAT
substrates and inhibitors, and D2 receptor agonists [215,384–387].
In particular, the trafﬁcking of DAT to and from the cell surface may
provide the predominant mechanism of acute DAT regulation
[388,389]. Since the subject of DAT regulation has been extensively
covered [388–390], we will only brieﬂy summarize some of the key
mechanisms here.
2.2.1. DAT regulation by psychostimulants
Considerable evidence supports a role for DAT substrates, like
amphetamine, in inducing DAT internalization in vivo and in vitro,
thus decreasing DA uptake [391–396]. Interestingly, the effect of
DAT substrates is biphasic with a rapid and transient upregulation
in surface DAT levels followed by a more lasting downregulation
[397,398]. Regional differences have also been reported
[395,399,400]. Studies on DAT regulation by DAT blockers have
focused on the effects of cocaine, which blocks DAT internalization
induced by DAT substrates [392,393,397,398]. On the other hand,
cocaine’s action on DAT trafﬁcking per se is controversial [393,401–
403].
While several kinases are involved in the regulation of DAT, PKC
is by far the most thoroughly investigated [389,404]. PKC
activation induces DAT internalization [393,405–407], although
the mechanism of PKC activation by DAT substrates remains largely
unknown [389,390,404,408,409].
2.2.2. DAT regulation by D2 receptors
Activation of several GPCRs can also regulate DAT function
[388,389]. Studies using acute administration of agonists and
antagonists of the D2 receptor have established a positive
regulation of DAT activity and surface expression by D2 DA
autoreceptor activation in vivo and in vitro [410–416]. D2 receptor-
dependent upregulation of DAT activity may involve G-proteins,
ERK1/2 and PKA [411,415,417], with inhibition of ERK1/2 leading to
a decrease in DAT function and its cell-surface localization [418].
There is also evidence, albeit inconsistent, for co-localization
and direct interaction of DAT and D2 receptors. Association with
D2 receptors appears to promote DAT recruitment to the plasma
membrane [417]. Consistent with this result, Dickinson et al. [419]
found a decrease in DAT function in D2-deﬁcient mice, based on a
decreased rate of clearance of exogenously applied DA [419].
However, Benoit-Marand et al. [224] detected no effect on the DA
clearance of electrically evoked DA release in vivo in response to
electrical stimulation in D2-receptor knockout mice [224]. DA
uptake in striatal slices from D2-knockout mice showed increased
DAT function, and an enhanced effect of DAT inhibition [227]. Note
that pharmacological studies that addressed these interactions
typically involve acute inhibition or activation of D2 receptors,
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DAT function due to long-term or developmental effects of
D2 receptor deﬁciency.
2.3. Uptake limits the radius of DA diffusion in the extracellular space
EM studies of the striatum show that DA axons can form small
symmetrical synaptic contacts on the neck of dendritic spines of
medium spiny neurons [420]. The majority of postsynaptic DA
receptors appear to be extrasynaptic along dendritic membranes,
and often distant from DA synapses [420–423], although D1 and
D2 receptors are also found in the perisynaptic zone of asymmetric
synapses formed by glutamate terminals on the heads of dendritic
spines. This anatomy suggests that it is necessary for DA to
spillover from release sites to activate its receptors, and therefore
that DA transmission is mainly extrasynaptic [423]. Consistent
with this mode of action, DA uptake sites are rarely observed on the
presynaptic membrane and rather may be distributed evenly along
the membrane of DA ﬁbers [359,424,425].
In the striatum, the density of DA release sites is very high and
the average distance between two release sites is 4 mm [426]. It
should be noted that estimates of the fraction of purported striatal
DA release sites that includes a postsynaptic specialization may be
as low as 30% [427], so that DA “varicosities” or “boutons” are more
accurate terms than “synapse” or “terminal” to describe these.
The maximal amplitude of the DA overﬂow evoked by a single
stimulation pulse in the rodent striatum in vivo and detected using
a carbon-ﬁber microelectrode is in the range of 100–400 nM
[149,365,368,428]. This value may underestimate the change in
intact tissue; models of electrochemically detected changes in
[DA]o assume that there is a pool extending 6–8 mm between intact
tissue and the electrode surface, i.e., the dimensions of the
electrode tip diameter [95,428,429]. This estimate is consistent
with EM studies of the extent of tissue damage caused by a carbon-
ﬁber implanted for 4 h in the striatum of anesthetized rats [430].
Therefore, the DA overﬂow recorded by a carbon-ﬁber microelec-
trode may be much larger than that typically reported in
electrochemical studies.
In striatum, D1 receptors appear to be in a low afﬁnity state
(1 mM) whereas D2 receptors are in the high afﬁnity state (10 nM)
[431], although in vivo evidence for this is still lacking. It has been
estimated that the basal [DA]o resulting from tonic DA neuron
activity is in the range of 10–20 nM, which would be high enough
to exert a tonic stimulation of presynaptic [361] and postsynaptic
[432] D2 receptors.
There have been several models suggested to estimate DA
overﬂow in the striatum. In a model of diffusion of DA in the
extracellular space following a quantal release event [370], at short
distance (1 and 2 mm), diffusion entirely governs the DA overﬂow,
whereas at increasing distance from release site (5 to 20 mm), DA
uptake increasingly limits the DA overﬂow both in term of maximal
amplitude and duration. At the latter distance range, the maximal
amplitude of the DA overﬂow is below 100 nM. This model
therefore suggests that DA transmission mediated by D1 receptors,
assuming they are in the low afﬁnity state, occurs after DA release
from a single vesicle to a distance of 2 mm and is largely unaffected
by DA uptake. In contrast, DA transmission mediated by
D2 receptors might be effective at a distance of 7 mm from release
sites. This distance as well as the duration of effective D2
stimulation (i.e., time during which the extracellular DA concen-
tration exceeds 10 nM) is limited by DA uptake [370].
A similar approach [19] estimates that in the striatum, basal DA
release would bind to 0.1% of DA receptors, but within 5 ms after a
quantal event, 60–100% of DA receptors in a perisynaptic zone of
22 mm distance would be bound for nearly 1 s, depending on
quantal size. This system is immensely plastic: the “sphere ofinﬂuence” for which DA levels are >10 nm with a quantal size of
3000 molecules has a radius of 12 mm, but in the case of decreased
DAT, as in Parkinson’s disease, after L-DOPA can reach 32 mm,
corresponding to a 19-fold increase in striatal volume [145]. This
helps explain the remarkable efﬁcacy of L-DOPA in Parkinson’s as
long as there is some surviving SNc input to the dorsal striatum.
The view that released DA escapes release sites and its diffusion
is not strongly affected by uptake in the immediate vicinity (i.e.,
<5 mm) is supported by electrochemical measurements of evoked
DA overﬂow. Indeed, DAT inhibition strongly slows DA clearance
after single-pulse evoked release, but only moderately enhances
the maximal [DA]o amplitude [95,372,433].
In summary, the rising phase of the evoked [DA]o is rapid and
reﬂects mainly DA release, whereas the decay phase is slower and
reﬂects DA uptake. The kinetics of release and uptake can be
obtained by simulation, taking into account DA diffusion from the
intact tissue to the electrode surface. Simulations show that the
half-life of released DA in striatum in vivo is 30 ms
[95,372,428,429], which allows for diffusion of 7 mm. Of course,
given the dense innervation of the striatum, DA overﬂow from each
release site will contribute to spatial and temporal summation to
lead to larger, longer-lasting DA transients that are will be more
spatially constrained by DA uptake than are individual release
events [371].
In brain structures with lower DA innervation and consequently
lower DAT, including prefrontal and cingulate cortices, globus
pallidus, subthalamic nucleus, SNc and VTA, diffusion should play a
larger role in DA clearance of released DA. Even in sparsely
innervated regions, however, DAT inhibition may delay DA
clearance [374,375,434].
3. Relationship between DA neuron ﬁring and extracellular DA
DA neurons exhibit two main activity patterns: regularly spaced
spikes at 2–5 Hz, and brief higher-frequency bursts of 2–6 action
potentials [435,436]. Under resting conditions and during sleep,
most DA neurons show regular, tonic activity; however, adminis-
tration of a reward (e.g., food) or a sensory stimulus that predicts a
reward can trigger a burst of action potentials in most midbrain DA
neurons in monkeys [437,438] and rats [439]. In rats, the intra-
burst frequency is 15–30 Hz, but can be higher [435,4369]. Grace
and Bunney [435] hypothesized that bursting would be more
potent than tonic activity to induce DA release in distant striatal
regions. Consistently, electrical stimulation mimicking bursting is
twice as effective in increasing [DA]o in vivo as regularly spaced
tonic stimuli with the same duration or pulse number [440]. The
difference in efﬁcacy of tonic and burst ﬁring involves the
timecourse of DAT-mediated uptake.
3.1. Tonic [DA]o
With tonic DA neuron ﬁring, the pause between successive
action potentials exceeds 200 ms, so that DA released by one action
potential can be cleared by before the next action potential. The
role of uptake in maintaining [DA]o was demonstrated in vivo with
MFB stimulation at 4 Hz [441]. Synchronous activity can occur
between pairs of adjacent DA neurons recorded with the same
electrode [442,443], but not between pairs of distant neurons
recorded with two electrodes [442]. Moreover, synchrony of near-
neighbor ﬁring is more prominent during bursting activity [443].
Thus, given the very high density of striatal DA release sites
[424,426,427], and the extensively overlapping DA axonal arbors
[444], tonic activity induces a steady-state [DA]o, in the range of
10–30 nM, which is stable with time and spatially homogenous
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[432,445]. Indeed, pharmacological DAT inhibition uptake
increases [DA]o by 300% [363,428,445], consistent with the
500% higher [DA]o seen in DAT/ vs. DAT+/+ mice [367].
3.2. Phasic changes in [DA]o
Burst-like stimuli are more effective than tonic in evoking DA
overﬂow, in part because the shorter interpulse interval of bursts
allows less time for DAT-mediated clearance than with tonic ﬁring.
In addition to this consequence of DAT-mediated uptake, other
factors include short-term plasticity in DA release probability that
depend on ﬁring frequency. One confounding factor that contrib-
utes to apparent short-term plasticity is presynaptic nAChR
activation that promotes short-term depression (Fig. 2). Even
without the effects of nAChRs, presynaptic Ca2+-dependent
mechanisms govern an inverse relationship between initial and
subsequent DA release probability [178] reﬂecting classic Ca2
+-dependent regulation of short-term plasticity [446]. Brieﬂy,
when depolarization results in initially low DA release probability,
high frequencies can promote short-term facilitation of release
[178], presumably through summation of intracellular Ca2+ at
sufﬁciently short interpulse intervals.
In behaving rats, brief, spontaneous changes in [DA]o, termed
DA transients, occur with similar kinetics and amplitude to [DA]o
evoked by brief electrical stimulation [447,448]. DAT inhibition
increases the maximal amplitude and duration of spontaneous
transients [449]. In NAc, resolvable DA transients can result from
bursting activity of VTA DA neurons: NMDA-mediated excitatory
inputs to VTA DA neurons generate bursts [450–452]. Correspond-
ingly, VTA injections of NMDA and of NMDA antagonists in freely
moving rats alter the frequency of DA transients [453].
Although midbrain DA neurons initially respond to unpredicted
reward with a burst of activity, after intense training they respond
to a cue predicting a reward but no longer to the expected reward
in monkeys [437,438] and rats [454]. Electrochemical studies have
shown the same relationship between DA transients and reward or
cue predicting a reward in NAc [455]. DA neurons burst with
appetitive stimuli and are inhibited by aversive stimuli in monkeys
[438] and rats [454,456], and consistently, appetitive stimuli
trigger NAc DA transients, whereas aversive stimuli brieﬂy
decrease [DA]o [457], although these responses may arise from
different DA neuron subpopulations, particularly in VTA [458–
460]. For example, intense stress induced by social defeat enhances
burst ﬁring in a distinct subpopulation of VTA DA neurons in freely
moving rats, and is associated with increased frequency of DA
transients in NAc [461]. In summary, FCV recording of DA
transients in vivo generally supports the encoding of reward-
prediction related information revealed by studies of DA neuron
ﬁring rate. However, unlike the relatively standardized responses
of midbrain DA neurons [462], phasic DA transients that report
unpredicted reward and reward-predictive cues are highly speciﬁc
to striatal subregions: DA transients seen in NAc are not typically
detected in CPu [463].
4. Conclusions
The net [DA]o at any point in time results from a dynamic
equilibrium between release and uptake. Both are regulated by
mechanisms that range from DA neuron ﬁring to local intracellular
and intercellular regulatory signals within target regions. Tonic
activity of DA neurons translates into tonic [DA]o, whereas burst
activity apparently translates into transiently enhanced [DA]o,
which is also locally regulated. Overall, the moment-to-moment
interplay among ﬁring, release, uptake, and auto- and hetero-receptor-dependent modulation is not only dynamic, but state-
and region-dependent. A challenge of future studies will be to
determine the relative contributions of these factors in speciﬁc DA-
dependent behaviors.
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